News & Events about Stoke Therapeutics.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday...
Stoke Therapeutics (NASDAQ:STOK Get Rating) had its price objective reduced by research analysts at HC Wainwright from $70.00 to $35.00 in a note issued to investors on Monday, The Fly reports. The firm presently has a buy rating on the stock. HC Wainwrights price target...
Business Wire
2 months ago
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the...
Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 18, 2022 NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located...